Alpha -Tocopherol Tea Tree Oil
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Alpha -Tocopherol Tea Tree Oil
- Alpha-Tocopherol + Tea Tree Oil: Insufficient Data for Repurposing Evaluation
Alpha-Tocopherol + Tea Tree Oil: Insufficient Data for Repurposing Evaluation
One-Sentence Summary
Alpha-Tocopherol (Vitamin E) combined with Tea Tree Oil is a topical agent combination with known antioxidant and antimicrobial properties, but no approved indication was identified in the US regulatory database for this specific combination product. The TxGNN model was unable to generate repurposing predictions for this candidate — no predicted new indications, clinical trial linkages, or supporting literature were returned. This evaluation is currently data-insufficient and cannot proceed to a standard repurposing recommendation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None identified in regulatory database |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this candidate. Based on known pharmacological knowledge, Alpha-Tocopherol is a fat-soluble antioxidant (Vitamin E) that scavenges free radicals and protects cell membranes from lipid peroxidation. Tea Tree Oil (Melaleuca alternifolia extract) exhibits broad-spectrum antimicrobial, anti-inflammatory, and antifungal activity, primarily through disruption of microbial cell membranes.
As a combination, this pairing is most commonly encountered in topical dermatological preparations — wound care, acne, and nail fungal infection are typical empirical use cases. However, because the TxGNN pipeline returned zero predicted indications, no knowledge-graph–supported repurposing hypothesis could be formulated for this specific drug string.
The absence of a DrugBank ID is a likely root cause: the input string .ALPHA.-TOCOPHEROL; TEA TREE OIL represents a combination product rather than a single INN entity, preventing standard graph-based traversal. Disambiguation into individual components (Alpha-Tocopherol separately, Tea Tree Oil separately) may unlock predictions.
Clinical Trial Evidence
Currently no related clinical trials registered for this combination candidate under the queried indication scope.
Literature Evidence
Currently no related literature available via the current evidence pipeline for this candidate.
US Market Information
No US marketing authorizations were identified for the drug string .ALPHA.-TOCOPHEROL; TEA TREE OIL.
Note: Individual components (Alpha-Tocopherol / Vitamin E) do have extensive regulatory history as dietary supplements and excipients. Tea Tree Oil appears in OTC cosmetic and antiseptic products. However, the combination as a defined pharmaceutical product returned zero registrations in the queried database.
Safety Considerations
Please refer to the package insert for safety information. No structured safety data (warnings, contraindications, or drug interactions) was returned for this candidate in the current Evidence Pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline returned no predicted indications for this candidate, and zero regulatory records were identified — making a repurposing recommendation impossible at this stage. The root cause is most likely the non-standard input string (combination product rather than single INN), which prevents DrugBank ID resolution and knowledge-graph traversal.
To proceed, the following is needed:
- Disambiguate the input: Split into two separate INN queries — run
ALPHA-TOCOPHEROLandTEA TREE OIL(or its INN equivalent, Melaleuca alternifolia oil) through the TxGNN pipeline independently - Resolve DrugBank ID: Manually look up
DB00163(Vitamin E / Alpha-Tocopherol) and the Tea Tree Oil DrugBank entry to enable graph-based prediction - Confirm product intent: Clarify whether this is intended as a topical dermatological combination — if so, switch to the topical-product evaluation pathway
- Retrieve MOA data: Query DrugBank API for both components to populate mechanism data before re-running the evidence pack
- Re-run evidence collection after INN disambiguation to obtain clinical trial and literature linkages
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.